The Institute for Transuranium Elements (ITU) is one of seven Institutes of the European Commission´s Joint Research Centre (JRC). ITU provides the scientific foundation for the protection of the European citizen against risk associated with handling and storage of highly radioactive material.
The Institute of Transuranium Elements prime subjective are to serve as a reference centre for basic actinide research, to contribute to an effective safety and safeguards system for the nuclear fuel cycle, and to study technological and medical applications of radionuclides/actinides.
The facilities of the Alpha-immunotherapy action at ITU include laboratories for radionuclide production, radiobiological testing and organic synthesis. The image shows part of the laboratory dedicated to the production of alpha-particle emitters (e.g. 225Ac/213Bi and 230U/226Th) and radionuclide generators.
Since February 2009 there exists a signed collaboration agreement between The European Atomic Energy Community (under which JRC and ITU are organized) and the University of Gothenburg (under which the Departments of Oncology and Radiation Physics are organized). The co-ordinators for this collaboration are Dr. Frank Bruchertseifer for the JRC and Dr. Sture Lindegren for the University of Gothenburg.
Fig. 1. Please click image for higher resolution.
Generally, the collaboration consists of a joint effort so that new approaches can be identified and developed in the area of alpha-immunotherapy. This involves pre-clinical as well as clinical phases using various alpha-particle emitters and bio-molecules.
Initially, the collaboration consists of ITU supplying 213Bi generators to be used for evaluating the alpha-particle emitter 213Bi in different pre-clinical studies.